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ABSTRACT
MicroRNAs (miRNAs) are involved in a variety of human diseases by simultaneously suppressing many gene targets. Thus, the
therapeutic value of miRNAs has been intensely studied. However, there are potential limitations with miRNA-based
therapeutics such as a relatively moderate impact on gene target regulation and cellular phenotypic control. To address these
issues, we proposed to design new chimeric small RNAs (aiRNAs) by incorporating sequences from both miRNAs and siRNAs.
These aiRNAs not only inherited functions from natural miRNAs, but also gained new functions of gene knockdown in an
siRNA-like fashion. The improved efficacy of multifunctional aiRNAs was demonstrated in our study by design and testing of
an aiRNA that inherited the functions of both miR-200a and an AKT1-targeting siRNA for simultaneous suppression of cancer
cell motility and proliferation. The general principles of aiRNA design were further validated by engineering new aiRNAs
mimicking another miRNA, miR-9. By regulating multiple cellular functions, aiRNAs could be used as an improved tool over
miRNAs to target disease-related genes, thus alleviating our dependency on a limited number of miRNAs for the development
of RNAi-based therapeutics.
Keywords: microRNA; siRNA; RNA interference; target regulation; cancer therapy
INTRODUCTION
RNA interference (RNAi) is an RNA-guided gene silencing
process within living cells that controls the expression of the
targeted genes (Hannon 2002; Denli and Hannon 2003;
Sontheimer 2005). There are two major types of small RNA
molecules that are central to RNA interference: microRNAs
(miRNAs) and small interfering RNAs (siRNAs).
miRNAs are a family of small noncoding RNA molecules
(∼22 nucleotides, nt) that down-regulate the expression of
their gene targets (Miska 2005). More than 2000 human
miRNAs have been identified to date (Kozomara and
Griffiths-Jones 2011). Both computational and experimental
studies indicate that thousands of human protein-coding
genes are directly regulated by miRNAs (Lewis et al. 2005;
Lim et al. 2005; Miranda et al. 2006). Thus, miRNAs function
as master regulators for many important biological processes,
such as cell growth, differentiation, apoptosis, viral infection,
and cancer development (Ambros 2004; Miska 2005; Calin
and Croce 2006; Kent and Mendell 2006; Johnson et al.
2007).
Given the importance of miRNA-mediated gene regula-
tion in disease biology, the diagnostic and therapeutic poten-
tial of miRNAs has been extensively explored in recent years.
miRNAs are especially important in cancer development,
because multiple miRNAs have been shown to be tumor sup-
pressors or oncogenes (Croce 2009). To date, many studies
have been published on using miRNAs as diagnostic and
prognostic cancer biomarkers. In addition, clinical studies
are under way to manipulate the expression level of
miRNAs for the intervention of a variety of human diseases
including cancer (for review, see Wurdinger and Costa
2007; Tong and Nemunaitis 2008). For example, introduc-
tion of tumor-suppressive miRNAs in human cancers may
be an effective approach to suppress tumor growth (Kota
et al. 2009; Rossi 2009; Valastyan et al. 2009).
For most miRNA-based therapeutic studies, naturally pro-
cessed mature miRNAs are evaluated. One potential concern
is that these natural miRNAs may not have the desired effi-
cacy for functional gene regulation in therapeutic applica-
tions. In general, miRNA-mediated target suppression is
relatively moderate as compared with siRNA-mediated
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gene knockdown. Although a single miRNA can simultane-
ously target many genes, only a limited number of cellular
phenotypes may be observed. For example, miR-200a has a
significant impact on cancer metastasis by suppressing the
motility of cancer cells (Gregory et al. 2008; Park et al.
2008). However, miR-200a does not have any reported regu-
latory role in some other important cancer cell properties
such as proliferation or cell death.
The major goal of our study was to engineer new potent
small RNAs forRNAi-based therapy.To this end,weproposed
to improve the efficacyof disease-targetingmiRNAby rational
design of artificial interference RNA (termed “aiRNA” in our
study). These aiRNA molecules are miRNA–siRNA chime-
ras, which were designed in silico based on natural miRNA
as well as siRNA sequences. We hypothesized that, by simul-
taneously targeting genes frommultiple functional categories
that are related to the same disease, the therapeutic efficacy of
an aiRNA can be greatly enhanced as compared with a single
miRNA or siRNA. Specifically, we used human cancer as an
example to test this new approach and showed that an aiRNA
design based on miR-200a and AKT1 siRNA had enhanced
functional efficacy by simultaneously suppressing both the
motility and proliferation of cancer cells.
RESULTS
aiRNAs and miRNAs share similar targeting
characteristics
Our definition for “artificial interference RNA” (aiRNA) is as
follows: an RNA molecule that is not present in nature and
has a similar sequence length to naturally processed mature
miRNAs. By this definition, synthetic siRNAs can also
be considered as a special form of aiRNA. An siRNA is typi-
cally a chemically synthesized 21-mer RNA duplex, with one
strand having 100% sequence complementarity to a single
intended mRNA target. siRNAs are widely used to knock
down the expression of their gene targets. Thus, the analysis
of siRNAs will give us useful clues about the general proper-
ties of aiRNAs.
It has been shown in previous studies that introduction of
siRNAs into the cells can trigger widespread off-target effects.
Hundreds of unintended genes can be directly silenced by
siRNA overexpression (Jackson et al. 2003, 2006; Birming-
ham et al. 2006; Anderson et al. 2008). The seed region is de-
fined as positions 2–8 of a miRNA or siRNA sequence.
Similar to the seed pairing requirement in miRNA-mediated
gene targeting, recent studies indicate that many siRNA off-
targets have siRNA seed-pairing sites in the 3′ UTRs. In addi-
tion, bioinformatics analysis indicates that multiple targeting
determinants outside of the seed match, such as local AU
content and base composition at certain sequence positions,
are also shared by both miRNAs and siRNAs. Thus, in gene-
ral, siRNA off-targeting is very similar to gene expression
suppression by natural miRNAs. These studies suggest that
miRNAs and siRNAs enter identical or similar silencing com-
plexes and mediate similar effects on their targets (Nielsen
et al. 2007).
Given the high similarity between siRNA off-targeting and
miRNA target regulation, it is reasonable to expect that an al-
gorithm designed for miRNA target prediction should also
be applicable to the prediction of genes targeted by aiRNAs
(including siRNAs). To test this hypothesis, we analyzed the
off-target signature of an siRNA targeting GAPDH. The
siRNA off-targets were computationally predicted using
MirTarget2, which is an algorithm developed in our previous
study for miRNA target prediction (Wang 2008; Wang and
El Naqa 2008). A recent independent study has demonstrat-
ed that MirTarget2 (data retrieved from miRDB) (Wang
2008) has superior performance over other common target
prediction algorithms in comparative proteomic data
analysis (Mestdagh et al. 2011). To experimentally validate
MirTarget2 prediction results, the siRNA was overexpressed
in HeLa cells, and microarrays were performed to identify
siRNA off-targets globally at the transcriptome level. As
expected, the single intended target, GAPDH, was silenced
by the siRNA, with only 4% remaining mRNA level.
Interestingly, among all siRNA off-targets predicted by
MirTarget2, the majority were down-regulated by at least
10% (i.e., <90% remaining expression) (Fig. 1). Moreover,
more than one-fifth of all predicted off-targets were down-
regulated by at least 30%. The level of off-target suppression
is consistentwith previous observations that siRNAoff-targets
are generally silenced at a more moderate level as compared
with silencing of the intended targets (Jackson et al. 2003,
2006; Birmingham et al. 2006; Anderson et al. 2008). In con-
trast to the widespread down-regulation of predicted siRNA
off-targets, <5% of all genes expressed in HeLa cells were
down-regulated by 30% or more (Fig. 1, P = 3.5 × 10−17
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FIGURE 1. Microarrays to validate predicted siRNA off-targets. An
siRNA targeting GAPDH was transfected in HeLa cells, and the tran-
scripts down-regulated by the siRNA were globally identified with mi-
croarrays 24 h post-transfection. The graph shows the fraction of
down-regulated off-targets among all off-targets predicted by
MirTarget2 at various gene knockdown levels (represented by remaining
RNA expression level). Gene down-regulation was determined by refer-
encing to the negative control transfections.
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aiRNAs (exemplified by a GAPDH siRNA) and natural
miRNAs are similar, which opens a door to design aiRNAs
computationally to mimic or even enhance the functionality
of naturally processed miRNAs.
Design of multifunctional aiRNAs by mimicking both
miR-200a and AKT1 siRNA
We and others have previously shown that miRNA target
specificity is determined by multiple sequence features,
among which seed sequence match is the most critical deter-
minant. The dominant role of seed match in miRNA target
prediction was demonstrated here by comparing predicted
target sets of miRNAs from the miR-200 family, which is
known to suppress cancer cell motility by targeting multiple
genes involved in epithelial–mesenchymal transition (EMT),
leading to a significantly reduced ability of cancer cells to
migrate to distant sites to form metastatic lesions (Gregory
et al. 2008; Park et al. 2008). There are five members in
the miR-200 family. Among them, miR-200a and miR-141
share the same seed sequence, while miR-200b, miR-200c,
and miR-429 share a different seed sequence (Fig. 2A). For
any pair of miR-200 members, the predicted target sets
were almost identical if the seed sequence is shared by
both miRNAs (miR-200a/miR-141, miR-200b/miR-200c,
or miR-200b/miR-429, as shown in Fig. 2B). In contrast,
there was little overlap between predicted target sets if two
miRNAs have distinct seed sequences (even resulting from
a single base variation). Interestingly, differences in the 3′
portion of the miRNA sequence were much less important
than the seed region in target prediction. For example,
miR-200b and miR-429 sequences are different by eight bas-
es, yet the predicted targets sets for the twomiRNAs were still
highly similar (with >90% overlap) because both miRNAs
share the same seed region.
Given the utmost importance of seed sequence in deter-
mining miRNA targets, we hypothesized that aiRNAs sharing
the same seed sequence with miR-200a should also target a
very similar set of genes, leading to functional suppression
of tumor cell motility. These miR-200a-mimicking aiRNAs
are termed “aiR-200a” in our study. Furthermore, enhanced
tumor-suppressive functions could be achieved by rational
design of the non-seed sequence of aiR-200a. Specifically,
our design goal was to engineer novel aiRNAs that not only
share miR-200a functions for suppressing tumor cell motili-
ty, but also bear new functions for suppressing tumor cell
proliferation. By simultaneously suppressing both the motil-
ity and proliferation of tumor cells, aiR-200a was expected to
have enhanced functions for tumor suppression as compared
with naturally processed miR-200a.
The anti-proliferation function of aiR-200awas engineered
by targeting awell-established oncogene, AKT1. AKT1 is not a
predicted target of any miR-200 family member. AKT1 pro-
motes the proliferation rate of cancer cells, and overexpres-
sion of AKT1 has been observed in many human cancers
(Bellacosa et al. 2005). By silencing AKT1, tumor growth
can be greatly suppressed. Thus, AKT1 has been explored as
an anti-cancer therapeutic target in many studies (for review,
see Bellacosa et al. 2005).
In our design algorithm for aiR-200a, the siRNA targeting
mechanism was invoked to knock down AKT1. The most
straightforward design would have been the selection of a po-
tent AKT1 siRNA that shares the same seed sequence with
miR-200a. However, no such siRNA could be designed
because the AKT1 transcript sequence does not contain any
miR-200a seed binding site. Thus, an alternative strategy
was employed to mimic AKT1 siRNA. Interestingly, previous
studies showed that siRNAs containing a few mismatched
bases to the target binding sites could still potentially knock
down their intended gene targets, similarly to perfectly
matched siRNAs (Jackson et al. 2003, 2006). Thus, AKT1-tar-
geting aiR-200a could potentially be designed by introducing
a few mismatched bases into an AKT1 siRNA. In this way,
these aiRNAsmay still silence AKT1 via RNAi-mediated tran-
script degradation despite the presence of base mismatches.
As the first step of aiR-200a design, we selected siRNAs to
target AKT1. Design of AKT1-targeting siRNAs was per-
formed using our recently developed tool, siOligo, which im-
plemented a machine learning algorithm for selection of
highly potent siRNAs (Wang et al. 2009). siOligo has been ex-
tensively validated experimentally for the design of hyper-
functional siRNAs, and it has been used for the design of
most siRNA products by Ambion/Applied Biosystems. With
siOligo, more than 1000 candidate siRNAs targeting AKT1
were evaluated, and 100 top-ranking siRNAs were selected
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FIGURE 2. Computational prediction of gene targets of the miR-200
family. (A) Sequences of five miRNAs in the miR-200 family. The
miRNA sequences were aligned to miR-200a, and identical bases to
miR-200a are represented by hyphens. The seed region of miR-200a is
underlined. (B) Pairwise comparison of gene sets targeted by different
miR-200 family members, as predicted by MirTarget2.
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selected siRNAs, we then designed candidate aiR-200a se-
quences by replacing the seed region of the siRNA sequence
with the miR-200a seed sequence. aiR-200a sequences with
the fewest number of mismatched bases to the corresponding
siRNAs were retained. In this way, three aiR-200a RNAs were
designed, with two to three mismatches in the seed region to
the corresponding AKT1 siRNAs (Fig. 3A). Specifically, one
aiR-200a RNA has two interspersed mismatches, while the
other two have two and three contiguous mismatches,
respectively.
By sharing the same seed region, aiR-200a RNAs and miR-
200a were expected to target similar gene sets. To confirm
this bioinformatically, MirTarget2 was employed for the pre-
diction of genes targeted by miR-200a and aiR-200a, respec-
tively, and the target sets were compared. As shown in Figure
3B, the vast majority of miR-200a targets were also targets of
all three aiR-200a RNAs, despite the fact that the 3′ portions
of aiR-200a and miR-200a were completely different.
Specifically, 91%, 84%, and 87% of all predicted miR-200a
targets were predicted to be targeted by the three aiRNA-
200a RNAs (aiRNA-200a-1, aiRNA-200a-3, and aiRNA-
200a-3), respectively.
Experimental validation of selected aiR-200a targets
The in silico–designed gene silencing capability of aiR-200a
was evaluated experimentally. As the first step of functional
validation, the suppression of three potential gene targets by
aiR-200a was analyzed, including AKT1, ZEB1, and ZEB2.
Among them, ZEB1 and ZEB2 are well-established miR-
200a targets that promote cancer metastasis (Gregory et al.
2008; Park et al. 2008), both of whichwere predicted to be tar-
geted by all three aiR-200a RNAs.
First, real-time RT-PCR was performed to assess gene
knockdown at the mRNA level. As shown in Figure 3C, all
three aiR-200a RNAs were able to significantly suppress
mRNA expression of both ZEB1 and ZEB2 by ∼50%, a level
comparable to that observed in miR-200a-mediated target
suppression. In contrast, neither of the two AKT1 siRNAs
was able to impact the expression of ZEB1 or ZEB2. On the
other hand, both AKT1 siRNAs, but not miR-200a, were
able to drastically silence the expression of AKT1 transcript
by >70%. As to the three aiR-200a RNAs, they behaved differ-
ently in AKT1 knockdown.One of them, aiR-200a-3, was able
to knock downAKT1 transcript by∼60%,while the other two
had insignificant impact on AKT1 knockdown. The divergent
capabilities of AKT1 knockdown by different aiR-200a RNAs
were also confirmed at the protein expression level. As shown
in Figure 3D, only aiR-200a-3, but not the other two aiRNAs,
was able to suppress AKT1 protein expression to a level sim-
ilar to that observed in siRNA-mediated AKT1 knockdown.
Interestingly, aiR-200a-3 has two adjacent mismatched bases
to the AKT1 transcript. In contrast, the other two aiRNAs
have either more mismatches or interspersed mismatches
(Fig. 2A). In summary, aiR-200a-3 met our design goal of si-
lencing both AKT1 and selected miR-200a targets. Thus, this
aiRNA was further evaluated for global target down-regula-
tion at the transcriptome level.
aiR-200a and miR-200a targeted similar sets of genes
globally
Global gene target regulation by aiR-200a-3was evaluated and
compared with miR-200a and AKT1 siRNAs at the transcrip-
tome level with RNA-seq analysis. With overexpression of
miR-200a, 70 genes were down-regulated by >40%, including
ZEB1 andZEB2,whichwere also targeted by aiRNA-200a-3 as
revealed by real-time RT-PCR (Fig. 4A). Among these 70
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FIGURE 3. Design and validation of aiRNA-200a. (A) Sequences of
three aiR-200a RNAs. These aiRNAs were designed to share the same
seed sequence with miR-200a, as well as have high sequence homology
to three distinct AKT1 siRNAs, respectively. The seed regions are under-
lined. Bases that are different from the corresponding siRNAs are high-
lighted in red. (B) Comparison of predicted gene targets by miR-200a
and aiR-200a. MirTarget2 was employed for the prediction of genes tar-
geted bymiR-200a and three aiR-200aRNAs, respectively. Each aiR-200a
RNA was compared with miR-200a for predicted target overlap. (C)
Real-time PCR to validate predicted target suppression by miR-200a
and aiR-200a. mRNA expression of three genes was assessed, including
AKT1 and two previously validated targets of miR-200a, ZEB1 and
ZEB2. miR-200a, three aiR-200a RNAs, and two AKT1 siRNAs were in-
dividually transfected into HeLa cells, and target gene expression was de-
termined by comparing with the negative control transfections. (D)
Western blotting to evaluate suppression of AKT1 protein expression
by miR-200a, aiR-200a RNAs, or AKT1 siRNAs in HeLa cells.
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3, including 31 targets down-regulated by >40% (Fig. 4B; list-
ed in Supplemental Table 1). In contrast, only a single miR-
200a target (1.4% of total) was down-regulated by >40% by
one of the two AKT1 siRNAs. Thus, most miR-200a targets
were also targets of aiR-200a-3, but not AKT siRNAs. On av-
erage, these genes were suppressed to comparable levels, 50%
and 38% bymiR-200a and aiR-200a-3, respectively (Fig. 4C);
in contrast, they were not suppressed by either of the two
AKT1 siRNAs (108%and 97%of the negative control, respec-
tively). In summary, both computational target prediction
and RNA-seq validation data demonstrated the high similar-
ity in global target regulation profiles by miR-200a and aiR-
200a-3.
Multifunctional suppression of cancer cells
by aiR-200a
By targeting multiple genes involved in EMT regulation (in-
cluding ZEB1 and ZEB2), miR-200a can suppress themotility
of cancer cells. Similarly, by mimicking miR-200a and target-
ing similar sets of genes, aiR-200a was also expected to be a
suppressor for cell motility. This hypothesis was tested exper-
imentally with transwell cell migration assays. aiR-200a-3 was
overexpressed in HeLa cells, and the impact on cell motility
was compared with miR-200a, AKT1 siRNAs, and negative
controls. As shown in Figure 5A, both aiR-200a-3 and miR-
200a, but not AKT1 siRNAs, were able to significantly sup-
press cell migration by ∼60%. Thus, by mimicking miR-
200a, aiR-200a-3 inherited the function from miR-200a for
suppression of cancer cell motility.
A newly gained function of aiR-200a-3 by in silico design
was the ability to suppress cancer cell proliferation through
targeting AKT1. To test this additional function, MTS cell
proliferation assays were performed to evaluate the anti-pro-
liferation potential of aiR-200a-3, which was capable of sup-
pressing AKT1 expression (Fig. 3). Similar to AKT1 siRNAs,
overexpression of aiR-200a-3 led to a significant reduction





























































FIGURE 4. Global characterization of gene targets of aiRNA-200a with RNA-seq analysis. miR-200a, aiR-200a-3, and two AKT1 siRNAs were indi-
vidually transfected into HeLa cells, and the global impact on the transcriptome was assessed with RNA-seq analysis. The sequencing data were nor-
malized and log2-transformed. Gene down-regulation was determined by comparing it with the negative control transfections. In this way, 70 gene
targets of miR-200a (down-regulated by at least 40%) were identified. (A) Expression profile of 70 genes targeted by miR-200a. The expression levels
of these miR-200a targets were compared under various treatment conditions (i.e., overexpression of miR-200a, aiR-200a-3, or AKT1 siRNA) in order
to identify gene targets shared by miR-200a and aiR-200a-3/siRNA. (B) Percentages of miR-200a targets that were also suppressed by aiR-200a-3 or
AKT1 siRNA at various remaining expression levels. (C) Average level of suppression of miR-200a targets by miR-200a, aiR-200a-3, or AKT1 siRNAs.
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overexpression of miR-200a had no impact on cell prolifera-
tion. Thus, aiR-200a-3 was able to simultaneously suppress
both cancer cell migration and proliferation, whereas miR-
200a and AKT1 siRNA were only able to suppress either
cell migration or proliferation, but not both.
Additional design of multifunctional aiRNAs
by mimicking both miR-9 and TP53 siRNA
We further tested the hypothesis that the principles used for
aiR-200a design can be generalized for the design of other
aiRNA species by mimicking other miRNAs and siRNAs.
To this end, aiR-9 aiRNAs mimicking both miR-9 and
TP53 siRNAs were designed. miR-9 is capable of promoting
cancer cell motility as shown in previous studies (Ma et al.
2010; Wang et al. 2011), and TP53 is a well-characterized tu-
mor suppressor that promotes cancer cell death under che-
motherapy. Thus, by mimicking both miR-9 and TP53
siRNA, aiR-9 was expected to resemble a “hyperfunctional
oncogene” by promoting cancer cell motility and also avoid-
ing cell death under chemotherapy. Although not practically
useful as far as cancer cell killing is concerned, successful de-
sign of aiR-9 nevertheless would show that the general princi-
ples of aiRNA design can be broadly applied to flexibly
engineer new small RNAs targeting different combinations
of cellular functions.
As the first step of aiR-9 design, the siOligo algorithm was
used to select potent siRNAs targeting TP53 (Wang et al.
2009), as similarly described in detail for the design of aiR-
200a. Then, candidate aiR-9 sequences were designed by re-
placing the seed region of the siRNA sequences with the
miR-9 seed. In this way, three aiR-9 RNAs were designed,
with one or two mismatches in the seed region to the corre-
sponding TP53 siRNAs (Fig. 6A).
We evaluated the impact of aiR-9 on regulating the expres-
sion of TP53, as well as two previously validated miR-9 tar-
gets, ALCAM 9 (Wang et al. 2011) and FSTL1 (both are
involved in regulating cell motility) (data not shown) by
real-time RT-PCR. As shown in Figure 6B, all three aiR-9
RNAs, but not TP53 siRNA, were able to significantly sup-
press the expression of both targets of miR-9. However,
only one aiR-9, aiR-9-2, was also able to effectively suppress
the expression of TP53. Thus, aiR-9-2 was selected for further
functional validation because it met our design goal of sup-
pressing both TP53 and selected miR-9 targets. The impact
of aiR-9 on cell motility was evaluated in HeLa cells, in which
TP53 functions were abrogated byHPV-induced protein deg-
radation (Scheffner et al. 1990). As shown in Figure 7A, both
miR-9 and aiR-9-2were able to significantly promote cellmo-
tility by 44%and 57%, respectively, as comparedwith the neg-
ative control. Thus, as expected by design, aiR-9-2 inherited
the ability from miR-9 for promoting cell mobility. On the
other hand, aiR-9 was also able to resemble the phenotype



















































FIGURE 5. Functional characterization of aiR-200a for suppression of
both the motility and proliferation of cancer cells. miR-200a, aiR-200a-
3, or two AKT1 siRNAs were individually transfected into HeLa cells,
and changes in cell motility or proliferation were determined by com-
paring them with the negative control transfections. (A) Transwell mi-
gration assays to assess changes in cell motility. (B) MTS assays to assess



































FIGURE 6. Design and validation of aiRNA-9. (A) Sequences of three
aiR-9 RNAs. These aiRNAs were designed to share the same seed se-
quence withmiR-9, as well as have high sequence homology to three dis-
tinct TP53 siRNAs, respectively. The seed regions are underlined. Bases
that are different from the corresponding siRNAs are highlighted in red.
(B) Real-time PCR to validate predicted target suppression by aiR-9.
mRNA expression of three genes was assessed, including TP53 and
two previously validated targets of miR-9, ALCAM and FSTL1. miR-
9, three aiR-9 RNAs, and TP53 siRNA were individually transfected
into HeLa cells, and target gene expression was determined by compar-
ing it with the negative control transfections.
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aiR-9 overexpression and TP53 knockout led to drastic sup-
pression of cisplatin-induced cell death as evaluated by flow
cytometry analysis of sub-G1 cell population (Fig. 7B).
DISCUSSION
Because a single miRNA can regulate a large number of gene
targets, miRNAs can potentially function as master switches
to regulate a large portion of gene regulatory networks. The
ability of multitargeting by miRNAs is important to simulta-
neously regulate multiple potentially redundant biological
pathways, leading to observable cellular phenotypes. Thus,
miRNAs have been intensely studied as potential therapeutic
agents to treat a variety of human diseases. Based on the clin-
ical importance of miRNAs, we further proposed to design
aiRNAs as an improved strategy for disease treatment. Our
approach may potentially alleviate the dependency on a lim-
ited number of natural miRNAs by rationally designing and
testing a large number of aiRNAs for improved therapeutic
efficacy. In our study, we have shown that an aiRNAmimick-
ing miR-200a not only inherited the anti-metastatic capacity
of miR-200a, but also gained the new function of anti-prolif-
eration by mimicking an AKT1 siRNA. Thus, the aiRNA is
considered to function equivalently to a combination of
miR-200a and AKT1 siRNA. The general design principles
were further validated by testing aiRNAs that mimic both
miR-9 and TP53 siRNA.
A major advantage of a single multifunctional aiRNA
compared with multiple miRNAs or siRNAs is that there
are fewer small RNA molecules that compete for entering
the RNAi machinery, thereby minimizing potential toxic ef-
fects (Grimm et al. 2006; Jackson and Linsley 2010). In addi-
tion, distinct sequences from multiple combined miRNAs/
siRNAs will significantly boost undesired sequence-specif-
ic off-target effects. Furthermore, the inclusion of a single
aiRNA (in contrast to multiple miRNAs/siRNAs) will great-
ly simplify the therapeutic delivery process, because the
pharmacokinetics and pharmacodynamics of every miRNA
or siRNA included in delivery have to be closely mon-
itored. In summary, a single multifunctional aiRNA is likely
to be a more effective approach involving fewer potential
side effects.
Relevant to our work, recent studies have proposed alter-
native designs of multitarget small RNAs to suppress a pair
of distinct gene targets by using two active strands in an
siRNA duplex, or suppress several functionally redundant
genes from the same family by targeting homologous binding
sites in the transcripts (De Guire et al. 2010; Tiemann et al.
2010; Saetrom 2013). For these design strategies, the number
of intended targets is limited. In contrast, we propose to use
the seed sequence of natural miRNAs for aiRNA design, thus
inheriting the functions of miRNAs by suppressing many in-
tended miRNA targets. As shown by both bioinformatics and
RNA-seq analyses, the target profiles of seed-sharing aiRNAs
and miRNAs are highly similar. Therefore, undesired off-tar-
get effects from aiRNAs will be greatly reduced. Our aiRNA
design strategy is expected to be useful for the development
of new RNAi therapeutics, in which multiple genes need to
be targeted simultaneously. This represents a potentially po-
tent strategy for more effective disease control such as trigger-
ing synthetic lethality in cancer treatment. Our aiRNA design
principle can be generalized to broadly target other human
diseases in addition to cancer.
Previous studies indicate that an siRNA with a few mis-
matched bases to the target binding site may still potentially
suppress the expression of its intended gene target.
However, no well-defined rules have been established to cor-
relate siRNA knockdown efficiency to the composition of
mismatches in the seed region. In our limited analysis of three
aiRNAs designed to target AKT1, one inherited the knock-
down capacity from the corresponding siRNA, despite the
presence of two contiguous mismatched bases. In contrast,
the other aiRNAs were unable to knock down AKT1, due to
either three contiguous mismatches or two interspersed mis-
matches. Thus, it seems that both the number and positions of
the mismatches in the seed region can impact aiRNA knock-
down efficiency in an siRNA-like fashion. A similar design












FIGURE 7. Functional characterization of aiR-9 on cell motility and
cell death. (A) Impact of aiR-9 on cell motility. miR-9, aiR-9-2, and neg-
ative control RNA were individually transfected into HeLa cells, and
changes in cell motility were determined by transwell migration assay.
miR-9 and aiR-9-2 overexpression led to increased cell mobility to
144% and 157% on average, respectively, as compared with the control.
One representative microscope image from each assay is presented here.
(B) Impact of aiR-9 on cell death. TP53 deficiency renders HCT116 cells
resistance to cisplatin-induced cell death. HCT116 cells and HCT116
p53−/− cells were treated with cisplatin (50 µM), and cell death was de-
termined as sub-G1 population by flow cytometry analysis after DNA PI
staining. Furthermore, HCT116 cells were transfected with negative
control RNA, aiR-9-2, or miR-9 individually followed by cisplatin treat-
ment, and then analyzed by flow cytometry for cell death with PI
staining.
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success rate was also observed when designing aiRNAs to tar-
get TP53. To further improve design success rate, a large num-
ber of aiRNAs with various mismatch compositions would
need to be analyzed experimentally in the future to elucidate
the rules of mismatch tolerance, which would eventually lead
to significant algorithmic improvement.
In our study, siRNAs are considered as a special form of
aiRNA, and they share similar characteristics with miRNAs
and other types of aiRNA for multitargeting, which is com-
monly known as siRNA off-target effects. Off-targeting is an
intrinsic property of siRNAs, and thus its impact should be
thoroughly considered in RNAi therapeutics. Our work indi-
cated that, by modifying the seed region of an siRNA, wewere
able to convert unintended off-target effects into intended
miRNA-like “on-target” suppression. This provides new
insights into the design of potent siRNA-based therapeutics by
using the multitarget nature of siRNAs. Although miRNAs
and siRNAs are still two distinct therapeutic strategies at pres-
ent, we envision that the boundary defining the two would be
blurred in future, because it is possible to design aiRNAs that




HeLa cells or HCT116 cells were transfected with synthetic miRNAs
or siRNAs (Sigma-Aldrich) and Lipofectamine 2000 (Life
Technologies). Negative controls included both transfection with
a negative-control small RNA (with a random sequence) and trans-
fection with no RNA added, and the average readings from both
control transfections were used as the baseline reference for evaluat-
ing the impact of miRNA or siRNA overexpression. GAPDH siRNA
was used as a positive control to monitor the transfection efficiency
by real-time RT-PCR. Total RNA was extracted 24 h post-transfec-
tion using the mirVana RNA Isolation Kit (Life Technologies).
Real-time RT-PCR
Reverse transcription was performed with the High Capacity RT kit
(Life Technologies). All PCR primers were designed in our previous
study, and the sequences were retrieved from PrimerBank (Wang
et al. 2012). Real-time PCR was performed to determine the relative
expression levels of the transcripts. The PCR running protocol was
the same as previously described (Wang and Seed 2003). Both
GAPDH and β-actin were used as internal controls for gene expres-
sion normalization.
Western blot
Cells were harvested and lysed in RIPA buffer (Thermo Scientific)
and a protease inhibitor mixture tablet (Roche Applied Science).
The lysate was then centrifuged, and the protein supernatant was ap-
plied to SDS-PAGE. Separated protein bands on the gel were trans-
ferred to Immun-Blot PVDF membrane (Bio-Rad). The membrane
was first blocked with 5% non-fat milk in Tris-buffered saline (TBS,
pH 7.4) and then incubated with primary anti-AKT1 mAb (Cell
Signaling) or anti-β-Actin mAb (Sigma-Aldrich). After washing
with TBS, the blots were incubated with secondary anti-mouse IgG
mAb conjugated with horseradish peroxidase (Thermo Scientific).
Bound antibodies were visualized by HRP substrate (Millipore)
and chemiluminescent signal was detected on X-ray films.
Transwell migration assay
Cultured cells were resuspended and washed with PBS buffer. Fifty
thousand cells in 100 μL of serum-free medium were added to the
upper chamber of each Transwell (24-well insert with 8-μm pore
size from Costar). The lower chamber was filled with 600 μL of me-
dium containing 10% bovine serum. Cells were incubated for 6 h,
and cells on top of the membrane were removed with a cotton-
tipped swab. Cells that had migrated through the membrane were
fixed and stained with Hema-3 (Fisher Scientific) for counting.
Cell proliferation assay
Three days after transfection, the cell proliferation rate was deter-
mined with theMTS kit (Promega). In brief, 10 µL of MTS substrate
was added into each well containing 100 µL of 10% FBSmedium in a
96-well plate. The plate was then incubated for 3 h, and the signal
was measured using a BioTek ELx800 microplate reader.
Microarray
Microarrays were performed at the Washington University Genome
Center using the Illumina BeadChip platform. The RNA quality was
assessed by an Agilent 2100 Bioanalyzer (Agilent Technologies). The
RNA was first amplified with the MessageAmp TotalPrep kit (Life
Technologies). Amplified RNA samples were then applied to
BeadChip arrays according to the manufacturer’s protocols for hy-
bridization and washing. Arrays were scanned with a Illumina
BeadArray Reader, and images were analyzed by Illumina Beadscan
and Beadstudio software. On-slide spot replicates were averaged
and reported. Rawarray datawere normalizedusing thequantile nor-
malization method.
RNA-seq
Total RNA was used to construct cDNA libraries for high-through-
put RNA sequencing. First, ribosomal RNA (rRNA) was removed
using the RiboMinus kit (Life Technologies) and custom designed
rRNA oligonucleotide probes, following the manufacturer’s proto-
col. rRNA-depleted total RNA was then used as template to con-
struct RNA-seq libraries with the NEBNext mRNA Library Prep
kit (New England BioLabs). In brief, double-stranded cDNA was
synthesized from rRNA-depleted total RNA, end repaired, dA tailed,
and then ligated to standard Illumina adaptor oligos. Adaptor-ligat-
ed cDNA libraries were amplified using Phusion PCR master mix.
Amplified cDNA libraries were loaded into HiSeq 2000 (Illumina)
for sequencing at the Washington University Genome Center. The
resulting raw sequence reads were preprocessed with a custom
bioinformatics pipeline to remove low-quality reads and clustered
before mapping to the human transcriptome and genome (version
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19) with Bowtie (Langmead et al. 2009). In this way, ∼90% of all se-
quence reads were mapped to human sequences. Sequence reads
mapped to the same transcript were combined and then normalized
by the length of the transcript as well as the number of total reads
from each sample (reads per kilobase per million, RPKM).
Normalized read counts were compared across samples to assess
changes in transcript abundance, and are listed in Supplemental
Table 2. Transcripts from the same gene locus were combined for
evaluation of expression changes at the gene level.
Flow cytometry
HCT116 and HCT116 p53−/− cells were cultured in DMEM with
10% FBS. Cisplatin, DNase-free RNase, and Propidum Iodide (PI)
were purchased from Sigma-Aldrich. After treatment with cisplatin
(50 µM), all cells (both floating and attached) were collected, washed
once with DPBS, and then fixed with 70% ethanol on ice for at least
30 min. Fixed cells were washed twice with DPBS and then stained
with PI solution (25 µg/mL PI and 100 µg/mL DNase-free RNase di-
luted in PBS) for 1 h at room temperature avoiding light exposure.
Data were acquired by BD Aris FACS and analyzed using Flowing
Software 2 version 2.5.0 (Finland).
DATA DEPOSITION
The microarray data were deposited in the NCBI GEO database
(accession no. GSE41924).
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